NSRX — Nasus Pharma Ltd
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 2029039 ·
Last close
$2.83
Market Cap
$33.14M
52W High
$5.20
52W Low
$1.98
ADV30
102,595
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 5,004,000 | 1,237,000 | 2,236,000 |
| Jun 2025 | — | — | — | — | 639,000 | 203,000 | 4,953,000 |
| Dec 2024 | — | — | — | — | 717,000 | 284,000 | 3,929,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-18,520,000
Inventory
—
Receivables
—
ST Investments
$3,049,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -4,904,000 | -5,856,000 | 5,004,000 | 2,236,000 | — | -4,918,000 |
| Dec 2024 | 0 | -1,078,000 | -1,532,000 | 717,000 | 3,929,000 | — | -665,000 |
| Dec 2023 | 0 | -1,147,000 | -1,051,000 | 444,000 | 4,241,000 | — | -1,029,000 |
| Dec 2022 | 0 | -2,042,000 | -1,711,000 | 417,000 | 3,202,000 | — | -1,211,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BOLD | Boundless Bio, Inc. | $33.02M | $1.47 | — |
| ABVC | ABVC BIOPHARMA, INC. | $33.54M | $1.29 | — |
| TVRD | Tvardi Therapeutics, Inc. | $32.27M | $3.44 | — |
| NNVC | NANOVIRICIDES, INC. | $34.40M | $1.51 | — |
| NRSN | NeuroSense Therapeutics Ltd. | $31.48M | $0.87 | — |
News headlines (Yahoo Finance, 1h cache)
NSRX: Initiating Coverage – Sniffing Out a Better Solution
2026-05-22 07:00 · Yahoo
Nasus Pharma to Participate in Upcoming Investor Conferences
2026-05-01 13:14 · Yahoo
RedChip's Biotech Virtual Investor Conference Replays Now Available
2026-04-21 19:00 · Yahoo
RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
2026-04-07 15:00 · Yahoo
Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
2026-03-25 13:00 · Yahoo
BriefCast Publishes Transcript: Nasus Pharma NS002 Phase 2 Positive Topline Results Webinar Transcript
2026-03-19 14:06 · Yahoo
NSRX: NS002 Phase II Topline Results
2026-03-16 13:17 · Yahoo
Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therap
2026-03-16 11:30 · Yahoo
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
2026-03-13 12:35 · Yahoo
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
2026-03-10 14:21 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.